BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY Russian patent published in 2011 - IPC A61K39/395 C07K16/30 C07K16/18 A61P35/00

Abstract RU 2433831 C2

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and deals with bispecific binding agents for modulating biological activity. Essence of invention includes bispecific binding agent, which is cable of directed action on cancer cells by means of binding domain with high affinity with respect to first marker of cell surface, which does not induce significant biological effect, and binding domain with low affinity, which specifically binds with second marker of cell surface, producing significant and required biological effect. Also claimed are pharmaceutical compositions for treatment of malignant tumour, their application for production of medication and sets for diagnostics and visualisation of tumour.

EFFECT: intensification of antitumor action.

37 cl, 7 ex, 2 tbl

Similar patents RU2433831C2

Title	Year	Author	Number
MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2	2003	Koll' Khans Bossenmajer Birgit Mjuller Khans-Joakhim Slivkovski Mark K. Kelsi Stefen Majkl	RU2338751C2
PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS	2003	Krejsh Khans-Georg Shmidt Jurgen	RU2354402C2
BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES	2016	Moskaleva Olga Vasilevna Ulitin Andrej Borisovich Solovev Valerij Vladimirovich Zaripova Dina Anvarovna Vladimirova Anna Konstantinovna Nemankin Timofej Aleksandrovich Shmakova Aleksandra Pavlovna Shitikova Viktoriya Olegovna Artyukhova Marina Vladimirovna Diduk Sergej Vasilevich Torokhin Andrej Alekseevich Krapivin Bogdan Nikolaevich Grachev Aleksandr Valerevich Ivanov Roman Alekseevich Morozov Dmitrij Valentinovich	RU2653443C2
HUMANIZED ANTIBODY THAT SHOWS CAPACITY TO BIND ErbB2 AND BLOCK ACTIVATION OF ErbB2 RECEPTOR BY LIGAND (VARIANTS) AND COMPOSITION FOR USING IN CANCER TREATMENT COMPRISING THIS ANTIBODY	2000	Adams Kamellia U. Presta Lenard G. Slivkovski Mark	RU2270029C2
COMPOSITIONS FOR T-CELL THERAPY WITH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF	2018	Irvine, Darrell, J. Ma, Leyuan	RU2819805C2
IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES	2019	Bakhmann, Mikhael	RU2824391C2
MULTIVALENT ANTIGEN-BINDING FV MOLECULE	2011		RU2613368C2
METHOD FOR SELECTION AND PRODUCTION OF SELECTIVE AND MULTISPECIFIC THERAPEUTIC MOLECULES WITH SPECIFIED PROPERTIES, INCLUDING, AT LEAST TWO, DIFFERENT TARGET GROUPS, AND THEIR APPLICATIONS	2013	Khajndl Diter Khyulsmann Peter Mikhel Kalutsa Brigitt Kopetski Erkhard Niderfellner Gerkhard Tifentaler Georg	RU2644263C2
CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS	2018	Davila, Marko L.	RU2800922C2
ALPHA5-BETA 1 ANTIBODIES AND USING THEM	2009	Bender Stiven Li Kasperson Dzheral'D Frajes Khu-Lou, Dana Dan Tszjan Sin' Li Gan Nort Majkl Ajdan Van Tszjan'In Uikman Grant Brams Peter Khuan Khajchun' Devo Bridzhit Chehn' Khajbin' Tanamachi Don M. Toj Kristofer Jan Lan' Spraul Tim U. Jamanaka Mark	RU2528736C2

RU 2 433 831 C2

Authors

Nilsen Ulrik B.

Shoehberl' Birgit M.

Dates

2011-11-20—Published

2005-05-05—Filed